Blood Cancer &
 Leukemia

Leukemia Cancer News - Return to Menu

Dacogen(TM) (Decitabine) Injection Complete Response Accepted for Review By U.S. FDA

12/15/2005 - MGI PHARMA, INC. (Nasdaq:MOGN) and SuperGen, Inc. (Nasdaq:SUPG) today announced that the U.S. Food and Drug Administration (FDA) has accepted the Companies' resubmission as of November 15, 2005 as a complete response to the Approvable Letter for Dacogen(TM) (decitabine) injection for myelodysplastic syndromes (MDS). The resubmission has been classified by the FDA as a Class 2 response, and the FDA has established a user fee goal to review this response by May 15, 2006.

About Dacogen(TM) (Decitabine) Injection

Dacogen injection is a product candidate that belongs to a class of drugs called hypomethylating agents that is currently being evaluated in a broad clinical development program in patients with MDS, acute myeloid leukemia (AML), chronic myelogenous leukemia (CML), and solid tumors. Dacogen injection is not approved for marketing in the U.S. or by other regulatory agencies in their respective countries; therefore, safety and efficacy have not yet been established in any patient population. The Dacogen injection New Drug Application (NDA) is under review by the FDA for the MDS indication. A phase 3 EORTC-sponsored trial is currently ongoing in Europe to evaluate Dacogen injection in patients with MDS. MGI PHARMA is conducting a pivotal program to evaluate Dacogen injection in patients with AML. Additional clinical studies are also underway in patients with MDS to evaluate alternative dosing regimens for Dacogen injection.

About SuperGen

Based in Dublin, California, SuperGen is a pharmaceutical company dedicated to the acquisition, rapid development and commercialization of therapies for solid tumors, hematological malignancies and blood disorders. SuperGen's product portfolio includes Orathecin(TM) (rubitecan) capsules, an investigational drug being evaluated for the treatment of pancreatic cancer; Nipent(R) (pentostatin for injection), approved for the treatment of hairy-cell leukemia; Mitomycin, for use in the therapy of disseminated adenocarcinoma of the stomach or pancreas in proven combinations with other approved chemotherapeutic agents and as a palliative treatment when other modalities have failed; and SurfaceSafe(R) cleaner. For more information about SuperGen, please visit http://www.supergen.com.

About MGI PHARMA

MGI PHARMA, INC. is an oncology and acute care focused biopharmaceutical company that acquires, researches, develops and commercializes proprietary products that address the unmet needs of patients. MGI PHARMA markets Aloxi(R) (palonosetron hydrochloride) injection and Gliadel(R) Wafer (polifeprosan 20 with carmustine implant) in the United States. The company directly markets its products in the U.S. and collaborates with partners to reach international markets. For more information about MGI PHARMA, please visit www.mgipharma.com.

This news release contains certain "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are typically preceded by words such as "believes," "expects," "anticipates," "intends," "will," "may," "should," or similar expressions. These forward-looking statements are not guarantees of MGI PHARMA's or SuperGen's future performance and involve a number of risks and uncertainties that may cause actual results to differ materially from the results discussed in these statements. Factors that might cause the Companies' results to differ materially from those expressed or implied by such forward-looking statements include, but are not limited to, the ability of MGI PHARMA's and SuperGen's product candidates to be proven safe and effective in humans, to receive marketing authorization from regulatory authorities, and to ultimately compete successfully with other therapies; continued sales of MGI PHARMA's and SuperGen's marketed products; development or acquisition of additional products; reliance on contract manufacturing; changes in strategic alliances; continued access to capital; and other risks and uncertainties detailed from time to time in the Companies' filings with the Securities and Exchange Commission including their most recently filed Forms 10-Q or 10-K. MGI PHARMA and SuperGen undertake no duty to update any of these forward-looking statements to conform them to actual results.

CONTACT:
MGI PHARMA, INC. Jennifer M. Davis, 212-332-4381 E-mail: [email protected] or Noonan Russo for MGI PHARMA, INC. Robert Stanislaro, 212-845-4268 E-mail: [email protected] or About SuperGen, Inc. Timothy L. Enns, 925-560-0100 x111 E-mail: [email protected] or Noonan Russo for SuperGen, Inc. Sharon Weinstein, 212-845-4271 E-mail: [email protected]

NO WI-FI ON THIS CAMPUS

Friday, February 24, 2006 - FreeMarketNews.com

by staff reports
Canada's Lakehead University has limited the presence of Wi-Fi networks on its campus, over concerns about the "unproven" long-term safety of the systems, according to a story in the British technology publication The Register.

Fred Gilbert, university president, issued this order based on studies he had seen on possible links between radio transmissions and leukemia and brain tumors from sources including the California Public Utilities Commission.

"All Im saying is while the jurys out on this one, Im not going to put in place what is potential chronic exposure for our students," he reportedly said. "Admittedly thats highest around the locations of the antenna sites and the wireless hot spots, but those are the places people tend to gravitate to because they get the best reception."

Site Map | Acute Myelogenous Leukemia